TP53 in bone and soft tissue sarcomas.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Sarcomagenesis involves various genetic alterations, including fusion proteins and oncogenic drivers.
• The tumor suppressor p53 (TP53) is increasingly recognized for its role in suppressing bone and soft tissue sarcoma progression.
• While historically underestimated, TP53 mutations are now being uncovered in sarcomas like osteosarcoma through advanced genomic techniques.

Purpose of the Study:

• To explore the genomic and functional aspects of TP53 in nine specific bone and soft tissue sarcomas.
• To highlight the significance of TP53 alterations in sarcomagenesis and therapy resistance.
• To review emerging therapeutic strategies targeting TP53 in sarcomas.

Main Methods:

• Genomic analysis, including whole-genome sequencing, to identify TP53 alterations.
• Functional studies to understand the impact of wild-type and mutant p53.
• Review of current and novel therapeutic approaches targeting TP53.

Main Results:

• TP53 plays a critical tumor-suppressive role in osteosarcoma, Ewing sarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, liposarcoma, angiosarcoma, and undifferentiated pleomorphic sarcoma.
• Oncogenic gain-of-function activities of mutant p53 (mutp53) are implicated in sarcomas.
• Novel strategies targeting TP53 include restoring wild-type p53 (wtp53) activity, reactivating wtp53 from mutp53, depleting mutp53, and targeting TP53-deficient cells.

Conclusions:

• Understanding TP53 alterations is key to advancing sarcoma research.
• Emerging TP53-targeting therapies offer promise for treating therapy-resistant sarcomas.
• TP53 is a pivotal factor across a spectrum of bone and soft tissue sarcomas, presenting new therapeutic avenues.